Evidence map›Paper›PMID 28545589›Full record

Trial reportNutrition journal2017

Gastrointestinal tolerance of low FODMAP oral nutrition supplements in healthy human subjects: a randomized controlled trial.

Jennifer Erickson, Renee Korczak, Qi Wang, Joanne Slavin

Registry-linked trialOpen access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nutrition journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02667184 (The Effect of a Low FODMAP Oral Nutrition Supplement On Breath Hydrogen Response In Health Human Subjects), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02667184 nacompletednot on this map

The Effect of a Low FODMAP Oral Nutrition Supplement On Breath Hydrogen Response In Health Human Subjects

TypeinterventionalSponsorUniversity of MinnesotaRan2016 to 2016Enrolled21ConditionsFood SelectionArmsLow FODMAP Oral Nutrition Supplement
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. All that a physician should know about FODMAPs.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Jennifer EricksonDepartment of Food Science and Nutrition, University of Minnesota, 1334 Eckles Ave, St Paul, MN, 55108, USA.
Renee KorczakDepartment of Food Science and Nutrition, University of Minnesota, 1334 Eckles Ave, St Paul, MN, 55108, USA.
Qi WangClinical and Translational Science Institute, University of Minnesota, 717 Delaware St SE, Minneapolis, MN, 55414, USA.
Joanne SlavinDepartment of Food Science and Nutrition, University of Minnesota, 1334 Eckles Ave, St Paul, MN, 55108, USA. jslavin@umn.edu.
University of Minnesota · USSouthern California Clinical and Translational Science Institute · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere has been increasing interest in utilizing a diet low in fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs) for the treatment of irritable bowel syndrome (IBS), a functional gastrointestinal disease. While studies have indicated that this diet can be effective at symptom reduction, it is a restrictive diet and patients may find it challenging to find low FODMAP products to meet their nutrient needs. The primary objective of this study was to assess the gastrointestinal (GI) tolerance of three low FODMAP oral nutrition supplements (ONS) in healthy adults.

methodsA double-blind randomized controlled crossover study was conducted in 21 healthy adults (19-32 years). Fasted subjects consumed one of four treatments at each visit, with a one week wash out period between visits. Each participant received all treatments. Treatments included three low FODMAP ONS formulas (A, B, and C) as well as a positive control consisting of 5 g fructooligosaccharides (FOS) mixed in lactose-free milk. Breath hydrogen was measured at baseline, 1, 2, 3, and 4 h post treatment consumption. Subjective GI symptom questionnaires were completed at baseline, 0.5, 1, 1.5, 2, 3, 4, 12, 24 and 48 h following treatment consumption. Mean breath hydrogen concentrations and baseline corrected area under the curve for both breath hydrogen and GI symptoms were analyzed and compared between treatments. Significance was determined at P < 0.05.

resultsThe positive control resulted in higher breath hydrogen response compared to all three of the low FODMAP ONS beverages at 3 and 4 h after consumption. There were no differences in GI symptom response between treatments.

conclusionsAll treatments were well tolerated in healthy participants. The low FODMAP formulas resulted in a lower breath hydrogen response compared to the positive control, and may be better tolerated in individuals with IBS. More research should be conducted to better understand the GI tolerance of low FODMAP ONS in individuals with IBS.

trial registrationThe protocol for this study was registered on ClinicalTrials.gov in January 2016 (Clinical Trials ID: NCT02667184 ).

Indexed as

AdolescentAdultAgedBody Mass IndexCross-Over StudiesDietDietary CarbohydratesDietary FatsDietary FiberDietary ProteinsDietary SupplementsDisaccharidesDouble-Blind MethodFemaleFermentationGastrointestinal TractDietary CarbohydratesDietary FatsDietary FiberDietary ProteinsDisaccharidesMonosaccharidesOligosaccharidesPolymerspolyolBreath hydrogenFODMAPGastrointestinal toleranceOral nutrition supplement

Identifiers

PMID28545589
PMCPMC5445483
OpenAlexW2618249995

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.